Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
1.79%17.662.0%$111.93m
SAGESAGE Therapeutics, Inc.
1.80%160.939.5%$82.08m
JAZZJazz Pharmaceuticals Plc
0.49%125.932.2%$74.89m
ICPTIntercept Pharmaceuticals, Inc.
-0.34%110.8218.6%$68.57m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.53%150.496.3%$65.14m
PRGOPerrigo Co. Plc
0.76%48.976.8%$61.26m
PTLAPortola Pharmaceuticals, Inc.
3.86%30.967.7%$42.74m
CTLTCatalent Inc
1.06%42.022.4%$41.89m
ICLRICON Plc
0.67%145.054.1%$35.72m
UTHRUnited Therapeutics Corporation
0.92%119.6314.4%$31.22m
HZNPHorizon Pharma plc
1.05%23.177.4%$30.97m
CORTCorcept Therapeutics Incorporated.
3.69%11.805.5%$28.89m
AERIAerie Pharmaceuticals, Inc.
1.66%41.756.9%$28.04m
IRWDIronwood Pharmaceuticals, Inc. Class A
9.20%15.2010.1%$27.87m
MDCOMedicines Company
3.17%24.7721.8%$27.83m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.